Status:
COMPLETED
Immunity Persistence After Abridged Intradermal Rabies PEP
Lead Sponsor:
Institut Pasteur
Collaborating Sponsors:
Institut Pasteur du Cambodge
Institut Pasteur de Madagascar
Conditions:
Rabies
Eligibility:
All Genders
Phase:
NA
Brief Summary
After exposure, rabies can be prevented in almost 100% of cases by the administration of sufficient and timely post-exposure prophylaxis (PEP). PEP is based on wound cleansing, antisepsis, administrat...
Detailed Description
This is a multicenter, randomized, non-inferior clinical trial with samples for examinations and vaccination booster. To achieve this study, persons who previously received PEP and of any age (includ...
Eligibility Criteria
Inclusion
- person Identified in IP Cambodia or IP Madagascar records for having received ID PEP by 4 sessions/1 month or 3 sessions/1 week at least two, five or 10 years earlier, with no rabies boosting since that time;
- person Who received information adapter to his/her age and who signed the consent form (or his/her legal tutors)
Exclusion
- person who received Rabies vaccine booster since the earlier PEP
- person with allergy or other severe unwanted effect at the time of the earlier PEP
Key Trial Info
Start Date :
October 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2023
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04829630
Start Date
October 20 2021
End Date
February 1 2023
Last Update
March 9 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Pasteur du Cambodge
Phnom Penh, Cambodia
2
Institut Pasteur de Madagascar
Antananarivo, Madagascar, BP 1274